Market Closed - Nasdaq Helsinki 11:29:54 2024-04-26 am EDT 5-day change 1st Jan Change
4.11 EUR +3.01% Intraday chart for Optomed Oyj -0.84% +10.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Optomed Oyj, 2023 Earnings Call, Feb 15, 2024
Optomed Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Optomed Oyj Provides Revenue Guidance for the Full Year 2024 CI
Optomed Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Optomed Oyj Announces Nomination Board CI
Transcript : Optomed Oyj, Nine Months 2023 Earnings Call, Nov 03, 2023
Optomed Oyj Provides Revenue Guidance for the Year 2023 CI
Optomed Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Optomed to Raise EUR4 Million Via Share Issue MT
Optomed plc Announces Composition of Its Nomination Board CI
Optomed to Supply Large Diabetic Retinopathy Screening Solution to Spain CI
Transcript : Optomed Oyj, H1 2023 Earnings Call, Aug 04, 2023
Optomed Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Optomed Appoints Juho Himberg as the New CEO, Effective October 1, 2023 CI
Optomed Announces CEO Transition Plan CI
Optomed Oyj Approves Board Changes CI
Finland's Optomed Enters Distribution Partnership Deal With Thirona Retina MT
Transcript : Optomed Oyj, Q1 2023 Earnings Call, May 05, 2023
Optomed Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Optomed Plc Provides Revenue Guidance for the Full Year 2023 CI
Transcript : Optomed Oyj, 2022 Earnings Call, Feb 17, 2023
Optomed Oyj Provides Revenue Guidance for the Full Year of 2023 CI
Optomed Oyj Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Mars Duan Has Notifies Optomed plc That He Is Not Available for Re-Election CI
Transcript : Optomed Oyj, Q3 2022 Earnings Call, Nov 03, 2022
Chart Optomed Oyj
More charts
Optomed Oyj is a Finland-based medical technology company and a producer of handheld fundus cameras globally. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.11 EUR
Average target price
5.8 EUR
Spread / Average Target
+41.12%
Consensus
  1. Stock Market
  2. Equities
  3. OPTOMED Stock
  4. News Optomed Oyj
  5. Finland's Optomed Enters Distribution Partnership Deal With Thirona Retina